TD Cowen lifts UnitedHealth, Humana to Buy on improved earnings outlook

Résumé détaillé
TD Cowen upgraded UnitedHealth Group (NYSE: UNH) and Humana (NYSE: HUM) to Buy in notes on Friday. Telling investors that both health insurers have a clearer path to stronger…
Investing.com -- TD Cowen upgraded UnitedHealth Group (NYSE: UNH) and Humana (NYSE: HUM) to Buy in notes on Friday. Telling investors that both health insurers have a clearer path to stronger earnings now that pricing in Medicare Advantage, the private alternative to traditional Medicare, has become more rational.
Analyst Ryan Langston named UnitedHealth a best idea for 2027. He raised his price target to $455 from $402.
"We see UNH as an attractive story, with a credible path toward mid-high-teens EPS growth through 2028," Langston wrote.
Langston pointed to rational 2027 Medicare Advantage benefit designs, a multi-year recovery at Optum Health and improving commercial and Medicaid margins.
Stop chasing stocks after they've already rallied. Find your next investment opportunity with AI stock picks, earnings insights, and market-moving news. Yahoo! Finance readers get an extra 15% off on top of the 55% off Black Friday price. Join today! »
His estimates do not assume those segments fully recover, which he sees as about $2 per share of extra earnings potential. The stock trades at 12.9 times 2028 consensus EPS, below its five- and 10-year medians of 17.8 and 17.5 times.
He said recent CRUSH/RADV proposals and the potential for further regulatory/congressional impact are important near-term debates. "We see CMS communications of desired program stability and the lack of a cohesive message from congress on further MA reform as mitigating factors," he added.
For Humana, TD Cowen raised its price target to $485. The firm expects adjusted EPS of $40.42 in 2028, above the $37.81 consensus. It said major carriers, including Humana, prioritized profit over enrollment for 2027, and Humana cut over-the-counter benefits in sampled plans by 47%.
The firm said Humana's roughly 25% individual Medicare Advantage membership growth in 2026 expands its earnings base. The stock trades at about 9.5 times 2028 estimates.
Début de l'article, extrait de Yahoo Finance. Pour lire la suite, ouvrez l'article chez le média.
MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finance.yahoo.com)




